Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F McDermott

Showing results (81-90 of 666) with videos related to

Pageof 67
Sort By:
Seminars in Oncology|August 27, 2013
Immune therapy for kidney cancer: a second dawn?David F McDermott, Michael B Atkins
The American Journal of Psychiatry|June 11, 1975
Some guidelines for the training of foreign medical graduates: results of a special projectJ F Mcdermott, T W Maretzki
Hematology/Oncology Clinics of North America|June 2, 2014
Interferon, interleukin-2, and other cytokinesElizabeth I Buchbinder, David F McDermott
Journal of Veterinary Pharmacology and Therapeutics|October 3, 2020
Predicting antimicrobial susceptibility from the bacterial genome: A new paradigm for one health resistance monitoringPatrick F McDermott, James J Davis
Journal of Environmental Management|May 19, 2020
Water quality perceptions and private well management: The role of perceived risks, worry and controlG Schuitema, T Hooks, F McDermott
The American Journal of Psychiatry|April 11, 1975
Psychotherapy: historical roots, universal elements, and cultural variationsW S Tseng, J F Mcdermott
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 2007
More support for the judicious use of high-dose interleukin-2 in patients with advanced melanomaDavid F McDermott, Michael B Atkins
Expert Opinion on Biological Therapy|April 23, 2004
Application of IL-2 and other cytokines in renal cancerDavid F McDermott, Michael B Atkins
Clinical Advances in Hematology & Oncology : H&O|July 28, 2017
Combined blockade of vascular endothelial growth factor and programmed death 1 pathways in advanced kidney cancerDavid J Einstein, David F McDermott
Seminars in Oncology|October 19, 2006
Interleukin-2 therapy of metastatic renal cell carcinoma--predictors of responseDavid F McDermott, Michael B Atkins
Pageof 67

Showing results (81-90 of 666) with videos related to

Sort By:
Pageof 67
Seminars in Oncology|August 27, 2013
Immune therapy for kidney cancer: a second dawn?David F McDermott, Michael B Atkins
The American Journal of Psychiatry|June 11, 1975
Some guidelines for the training of foreign medical graduates: results of a special projectJ F Mcdermott, T W Maretzki
Hematology/Oncology Clinics of North America|June 2, 2014
Interferon, interleukin-2, and other cytokinesElizabeth I Buchbinder, David F McDermott
Journal of Veterinary Pharmacology and Therapeutics|October 3, 2020
Predicting antimicrobial susceptibility from the bacterial genome: A new paradigm for one health resistance monitoringPatrick F McDermott, James J Davis
Journal of Environmental Management|May 19, 2020
Water quality perceptions and private well management: The role of perceived risks, worry and controlG Schuitema, T Hooks, F McDermott
The American Journal of Psychiatry|April 11, 1975
Psychotherapy: historical roots, universal elements, and cultural variationsW S Tseng, J F Mcdermott
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 2007
More support for the judicious use of high-dose interleukin-2 in patients with advanced melanomaDavid F McDermott, Michael B Atkins
Expert Opinion on Biological Therapy|April 23, 2004
Application of IL-2 and other cytokines in renal cancerDavid F McDermott, Michael B Atkins
Clinical Advances in Hematology & Oncology : H&O|July 28, 2017
Combined blockade of vascular endothelial growth factor and programmed death 1 pathways in advanced kidney cancerDavid J Einstein, David F McDermott
Seminars in Oncology|October 19, 2006
Interleukin-2 therapy of metastatic renal cell carcinoma--predictors of responseDavid F McDermott, Michael B Atkins
Pageof 67